Ignite Creation Date:
2024-05-05 @ 9:46 PM
Last Modification Date:
2024-10-26 @ 10:08 AM
Study NCT ID:
NCT00952055
Status:
TERMINATED
Last Update Posted:
2015-01-16
First Post:
2009-07-31
Brief Title:
Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin
Sponsor:
Winthrop University Hospital
Organization:
Winthrop University Hospital
Study Overview
Official Title:
Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin
Status:
TERMINATED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
1 A delay in obtaining immunoassays to measure serum neopterin 2altered relevance of the expected experimental results to clinical practice
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome ACS patients by measuring serum neopterin levels Serum neopterin is a marker for measuring macrophage activation Prior studies have illustrated that there are elevated serum neopterin levels in ACS Patients enrolled are those with ACS Blood samples are drawn at presentation and at 72 hours after admission or at office visits and at 72 hours later Neopterin levels are measured via a commercially available assay
Detailed Description:
The study is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome ACS patients by measuring serum neopterin levels Serum neopterin is a marker for measuring macrophage activation Prior studies have illustrated that there are elevated serum neopterin levels in ACS The investigators study focused on comparing different treatment arms with regard to their neopterin levels and correlating neopterin levels to the Thrombolysis in Myocardial Infarction TIMI risk score Patients enrolled are those with ACS Blood samples are drawn at presentation and at 72 hours after admission or at office visits and at 72 hours later Neopterin levels are measured via a commercially available assay
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None